Prof. Bernard BIHAIN, Doctor of Medicine, Dr. Virginie OGIER, and Dr. Sandrine JACQUENET create the company GENCLIS as a contracted clinical research company. GENCLIS generates between 1 and 1.2 million Euros in revenue, with a profit greater than 20%.
GENCLIS organizes its first capital increase, in order to develop its own range of products. CM-CIC Investissement and the Institut Lorrain de Participation are involved in the capital increase.
GENCLIS is the first company to achieve the production and clinical validation of a recombinant test for the diagnosis of food allergy.This product changes clinical practice in regards to the diagnosis of peanut allergy and is licensed to PHADIA (now THERMO FISHER).The same year, GENCLIS files a patent protecting its discovery of transcription infidelity.
GENCLIS undertakes a program of translational research, aimed at establishing the clinical relevance of its discovery of RNA sequence heterogeneities, or RNA-DNA differences (RDDs).
GENCLIS competes and is awarded first prize (EUR 1 million) on behalf of the fondation INNABIOSANTE for its discovery of RDDs.
The concept of differences between DNA and RNA sequences is established and confirmed by several independent academic groups.
The National Institute of Health (NIH) grant GENCLIS unlimited access to clinical and sequencing data developed under the framework of The Cancer Genome Atlas (TCGA) program (TCGA Database).
GENCLIS obtains the first statistical evidence of a strong association between RDD levels and the severity of triple-negative breast cancer (TNBC).
GENCLIS begins marketing a range of allergenic products through partnerships with Hycor Biomedical (human market) and Galileo Diagnostics (veterinary market).
The measurement of RDD levels opens new perspectives in the detection of the severity of all major cancers.
The first range of SeveridiaTM products aims to predict the risk of recurrence of three cancers – TNBC, clear cell renal cell carcinoma, and bladder carcinoma – which are frequently characterized by the absence of recurrence after resection.